공고 • Jul 06
Atlas Energy Corp., Annual General Meeting, Aug 06, 2026 Atlas Energy Corp., Annual General Meeting, Aug 06, 2026. 공고 • Jun 22
Atlas Energy Corp. Announces Appointments to Subsidiary Board Atlas Energy Corp. announced that Patrick Drouin and Dion Degrand will be appointed to the board of directors of Atlas Energy International SEZC, the Company’s Cayman Islands subsidiary, subject to receipt of applicable Cayman Islands regulatory approvals. Patrick Drouin is the President of Wheaton Precious Metals International and Chief Sustainability Officer for the Wheaton group. Before being appointed President in October 2023, Mr. Drouin was the Senior Vice President of Sustainability & Investor Relations at Wheaton Precious Metals, an executive role primarily responsible for the company’s sustainability efforts and engaging with the investment community. Prior to Wheaton, Mr. Drouin worked for UBS Securities from 2001 to 2012 in institutional equity sales across North America and Europe, most recently in London as Head of European Sales for UBS Canada. In this role, Mr. Drouin built a sales platform responsible for advising fund managers on Canadian equities. Throughout his advisory career, he has focused on the resource sector. Prior to UBS, he served as a Project Geologist in the San Francisco Bay Area for William Lettis & Associates. Mr. Drouin has an MBA from the Rotman School of Management, University of Toronto, and a Masters in Geology from the University of Memphis. Dion Degrand is the Chief Executive Officer of the Rawlinson & Hunter group of companies in the Cayman Islands, providing a full range of professional services including fiduciary, trust and corporate, fund governance and administration, accounting, restructuring and compliance services to international clients. Mr. Degrand has over 30 years of experience across investment banking, public and private capital markets, accounting, international banking, and independent governance. Prior to relocating to the Cayman Islands, Mr. Degrand spent the majority of his career in oil and gas investment banking, holding senior positions at leading investment banks, including Head of Canadian Energy at Raymond James (Canada), Head of Energy and Head of Western Canada at Cormark Securities, Managing Director at National Bank Financial and Principal at Peters & Co. Limited. Mr. Degrand is a CA, CPA and CFA charterholder, and a CIMA-registered director under the Cayman Islands Directors Registration and Licensing Act. 공고 • May 07
Willow Biosciences Inc. announced that it expects to receive CAD 30 million in funding Willow Biosciences Inc. announced a private placement of 3,000,000,000 common shares and units at a price of CAD 0.01 for the gross proceeds of CAD 30,000,000 on May 7, 2025. Each unit will consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share at a price of CAD 0.01 per share. The Company may pay fees to certain advisory firms that assist in the placement of the Private Placement. Units will be issued to subscribers that are members of the New Executive Team and the New Board, together with certain additional subscribers identified by such persons. Common Shares will be issued to all other subscribers. The New Executive Team will be led by Mark Hodgson as President and Chief Executive Officer, Travis Doupe as Chief Financial Officer, Don Kornelsen as Vice President, Commercial, Ryan Giroux as Vice President, Corporate Development and Blair Anderson as Vice President, Geoscience of the Company and Richard Naden as a Senior Executive. The New Board will be comprised of Mark Hodgson, Richard F. McHardy, Gary Brown, Glenn McNamara and Scott Price. 공고 • May 01
Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million. Mycofeast Ltd entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million on March 14, 2025. The acquisition includes the Company's biotechnology business, intellectual property and R&D team. The consideration is subject to working capital and net debt closing adjustments. Closing of the Transaction is expected to occur on or about April 30, 2025, subject to customary closing conditions. The Transaction must be approved by shareholders holding at least 66.67% of shares voted in person or by proxy at an annual general and special meeting of shareholders, which will be held April 25, 2025 (the "Meeting"). The Transaction has been approved unanimously by Willow's Board of Directors, which has determined that the Transaction is in the best interests of Willow and its shareholders and unanimously recommends that shareholders vote in favour of approving the Transaction at the Meeting. Willow's major shareholders, Directors and Officers, who collectively control approximately 22.17% of the outstanding common shares of Willow, have each entered into a voting support agreement pursuant to which they have irrevocably agreed to vote all common shares in favour of the Transaction at the Meeting. The Company intends to apply a portion of the net proceeds to debt reduction, and will retain the remainder of the proceeds pending a review of its futures cash requirements and potential opportunities, with a view to maximizing shareholder value. Willow Biosciences Inc. must pay $0.5 million to Mycofeast Ltd if it terminates the deal. The deal is expected to be closed before April 30, 2025.
Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million on April 30, 2025. 
